Cambridge Healthtech Institute’s 2nd Annual

PROTACs and Targeted Protein Degradation – Part 2

Novel Protein Degraders

September 17-18, 2020


The ubiquitin-proteasome system (UPS) and the autophagy-lysosome system are the two major pathways responsible for protein degradation and maintenance of proteostasis. They consist of well-controlled, selective mechanisms for intracellular protein degradation and turnover. However, the diversity and complexity of the processes involved make it difficult to target these pathways for therapeutic intervention. The development of high-quality chemical probes, small molecule modulators, assays, and screening platforms have helped identify various UPS and autophagy targets, as well as novel chemical and biological degrades for discovery and therapeutic applications. Cambridge Healthtech Institute’s conference on PROTACs and Targeted Protein Degradation will bring together chemists, biologists, and pharmacologists to discuss the promise and challenges that lie ahead.

The UPS and autophagy pathways act as key regulators in cancer, CNS, and other diseases. Small molecules, such as proteolysis-targeting chimeras (PROTACs), E3 ligase modulators like thalidomides, DUB inhibitors, as well as other chemical and biological entities are being developed to hijack the UPS and trigger targeted protein degradation. However, some challenges do exist in terms of stability, biodistribution, and penetration of these molecules in vivo. The second part of the PROTACs and Targeted Protein Degradation conference will discuss ways to design and optimize these molecules for better in vitro to in vivo translation.

Preliminary Agenda


FEATURED PRESENTATION: Targeted Protein Degradation as a New Therapeutic Modality

Stewart Fisher, PhD, Chief Scientific Officer, C4 Therapeutics

Proteolysis Targeting Chimeras in Drug Development

Fiona Pachl, PhD, Senior Scientist, Chemical Biology and Proteomics, Biogen

Targeted Degradation of Therapeutic Targets Using bioPROTAC mRNA

Anthony Partridge, PhD, Senior Principal Scientist, Merck Sharp & Dohme

Biosensor Development Using CRISPR to Quantify Endogenous Protein Modulated by Targeted Protein Degraders

Chao-Tsung Yang, PhD, Principal Scientist, Research & Development, Eurofins DiscoverX


Strategies in the Design of Orally Active PROTAC Degraders for Clinical Development

Shaomeng Wang, PhD, Warner-Lambert/Parke-Davis Professor of Medicine, Pharmacology and Medicinal Chemistry; Co-Director, Molecular Therapeutics Program, University of Michigan; Director, Cancer Drug Discovery Program, University of Michigan

Hi-JAK-ing the Ubiquitin System: The Design and Physicochemical Optimisation of JAK PROTACs

Rishi Shah, PhD, Senior Scientist, Medicine Design, GSK

Degradation of Important Oncology Targets via PROTACs: TrkC and CDK4/6

Kevin Burgess, PhD, Rachal Professor of Chemistry, Texas A & M University


Using Proteolysis Targeting Chimera Technology to Overcome On-Target Drug Toxicity – A Story Behind DT2216

Daohong Zhou, MD, Professor, Department of Pharmacodynamics, College of Pharmacy, University of Florida at Gainesville

Acquired Resistance to BET-PROTACs Caused by Genomic Alterations in Core Components of E3 Ligase Complexes

Lu Zhang, PhD, Senior Scientist, Cancer Biology, Oncology Discovery, AbbVie Inc.

Targeted Protein Degradation for the Treatment of Cancer

Jing Liu, PhD, Executive Director, Medicinal Chemistry, Cullgen Inc.

Please click here to return to the agenda for PROTACs and Targeted Protein Degradation – Part 1

For more details on the conference, please contact:
Tanuja Koppal, PhD

Senior Conference Director

Cambridge Healthtech Institute



For partnering and sponsorship information, please contact:
Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286